Talazoparib plus hormone therapy for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy or cell testing (adenocarcinoma).
- Your cancer has spread (metastatic disease) to soft tissue and/or bone before starting hormone therapy.
- You can have had some hormone treatment already, but the timing must fit the study rules (no more than 60 days for new starts; specific limits if you had earlier treatment).
- Your health and blood counts must be adequate (Karnofsky 60–100, and lab values like blood counts, kidney function, and liver enzymes within set limits).
- You must have recent scans done near the start of hormone therapy so the team can document what’s there.
- You cannot have certain prior treatments or conditions, like prior chemotherapy for metastatic prostate cancer, brain metastases, and major uncontrolled heart or blood pressure problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding niraparib to standard hormone therapy (androgen ablation) after radiation works better for men with high-risk, localized or locally advanced prostate cancer. It may help control the cancer for longer, while also collecting extra tissue and blood to study why the treatment works or doesn’t.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests two drugs—talazoparib and enzalutamide—given together to men whose metastatic prostate cancer has worsened after treatment with abiraterone (Zytiga). The goal is to see if this combination can help control the cancer.
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Hear when a new Castration-Sensitive Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.